Intravenous Vitamin C Saves NZ Man with Flu Damaged Lung

chest-xray-1526779-639x626A 56 year old male was referred to Auckland Hospital ICU on 1 July 2009 with total respiratory failure, for ECMO external oxygenation. The patient had contracted H1N1 Swine flu (confirmed by tests) while on holiday overseas, and had developed what is known as ‘white out’ pneumonia. This refers to x-rays showing no air space in the lungs.

After 20 days of life-sustaining ECMO treatment and other critical care, the patient, who was unconscious by induced coma, had not responded. The ICU team advised the family of the likely outcome and had prepared them for the possibility of the patient’s death.

Family members approached Centre for Advanced Medicine Limited (CAM) for advice on the clinical use of intravenous vitamin C for such cases.

At the family’s request, information was provided to ICU doctors including ISO 9001:2008 registered protocols, safety data, dosages and access to vials of IV vitamin C under CAM’s license for wholesale medicines.

The ICU team agreed to administer intravenous vitamin C according to the family’s wishes. This decision acknowledged the family’s rights, in compliance with the New Zealand Health and Disability Act, 1997.

The patient received intravenous vitamin C starting on the evening of 21 July, continuing until 29 July. 25 grams was provided on the first day increasing over the first three days to 50 grams twice daily which was sustained for a further six days.

By 24 July x-rays indicated increasing lung function and ECMO external oxygenation was discontinued on 26 July. After several days of assisted ventilation and critical care for ongoing secondary conditions, the patient was able to commence his recovery and rehabilitation. The patient was discharged from hospital on Friday 18 September, and is recovering at home on the farm.

The decision by the Auckland Hospital ICU team to administer adequate dosages of IV vitamin C, and their skillful coordination of ICU procedures, were responsible for the positive medical outcome.

Permission from the patient and his family has been sought by CAM to publish these details on its website and elsewhere in the interests of accuracy. This permission was willingly provided and  CAM expresses its thanks, admiration and respect. CAM welcomes opportunities to provide similar professional support for registered medical practitioners and their patients.

Obtained from:

Oxidative DNA Damage and Lipid Peroxidation

EDTA chelation therapy, without added vitamin C, decreases oxidative DNA damage and lipid peroxidation.

by Roussel AM1, Hininger-Favier I, Waters RS, Osman M, Fernholz K, Anderson RA.


Chelation therapy is thought to not only remove contaminating metals but also to decrease free radical production. However, in standard ethylene diamine tetracetic acid (EDTA) chelation therapy, high doses of vitamin C with potential pro-oxidant effects are often added to the chelation solution. The authors demonstrated previously that the intravenous administration of the standard chelation cocktail, containing high amounts of vitamin C, resulted in an acute transitory pro-oxidant burst that should be avoided in the treatment of pathologies at risk of increased oxidative stress such as diabetes and cardiovascular disease. The current study was designed to determine the acute and chronic biochemical effects of chelation therapy on accepted clinical, antioxidant variables. An EDTA chelation cocktail not containing ascorbic acid was administered to six adult patients for five weeks (10 sessions of chelation therapy); antioxidant indicators were monitored. Immediately after the initial chelation session, in contrast with the data previously reported with the standard cocktail containing high doses of vitamin C, none of the oxidative stress markers were adversely modified. After five weeks, plasma peroxide levels, monitored by malondialdehyde, decreased by 20 percent, and DNA damage, monitored by formamidopyrimidine-DNA glycosylase (Fpg) sensitive sites, decreased by 22 percent. Remaining antioxidant-related variables did not change. In summary, this study demonstrates that multiple sessions of EDTA chelation therapy in combination with vitamins and minerals, but without added ascorbic acid, decreases oxidative stress. These results should be beneficial in the treatment of diseases associated with increased oxidative stress such as diabetes and cardiovascular diseases.